Studies on animal models of diabetes found that LIPEMF can restore the expression of Runx2 through the Wnt/β-catenin signaling pathway and reverse the deterioration of bone microstructure and strength, thereby preventing bone loss caused by diabetes, but has no effect on osteoclasts (143–145). The gene discussed is RUNX2; the disease is diabetes mellitus.